Issue of Equity and Total Voting Rights

London, UK - 23 February 2026, hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces the issue of 1,386,991 new Ordinary Shares of £0.001 each in the Company ("First Consideration Shares") to three managers of Cryo-Store Limited ("Cryostore"). This issuance comprises the first tranche (50%) of the equity consideration payable pursuant to the acquisition of Cryostore announced on 27 February 2025 (the "Acquisition").

The remaining tranche of up to 1,386,991 new Ordinary Shares ("Second Consideration Shares") will be issued on the second anniversary of the Acquisition, subject to the individuals remaining in service of the Group.

Application has been made for the First Consideration Shares to be admitted to trading on the AIM Market of the London Stock Exchange ("Admission"). It is expected that Admission will become effective and trading will commence at 8.00am on 26 February 2026.

Total Voting Rights

Following admission, the Company will have 688,401,079 Ordinary Shares in issue. This figure of 688,401,079 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Anthony Farrell, Niall Gilchrist